Literature DB >> 898233

The in vivo metabolism of progestins. IV. The metabolic clearance rate and plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in women.

C Gupta, J Osterman, M Miljković, C W Bardin.   

Abstract

[3H]6alpha-methylprogesterone (6MP) was synthesized by selective catalytic tritiation of the delta1-olefinic bond of 6alpha-methylpregna-1,4-diene-3,20-dione. The metabolic clearance rate of 6MP (MCR6MP) was determined in 6 women by the single injection technique. The plasma MCR6MP was 4047 +/- 298 L/day (59 +/- 15 L/day/kg) which was higher than the MCR of progesterone and medroxyprogesterone acetate (6alpha-methyl-17alpha-hydroxy-pregna-4-ene-3,20-dione acetate). The high clearance was not due to binding or metabolism of 6MP by red cells. Although 6MP was bound to CBG with a lower affinity than progesterone, this could not entirely explain the high MCR6MP. When considered with the reports of progesterone and medroxyprogesterone acetate clearance, the present studies suggest that the 6alpha-substitution of progesterone leads to an increased rate of steroid metabolism in women.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Endocrine System; Examinations And Diagnoses; Family Planning; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Medroxyprogesterone Acetate; Metabolic Effects; Physiology; Progestational Hormones; Progesterone; Research Methodology

Mesh:

Substances:

Year:  1977        PMID: 898233     DOI: 10.1016/0039-128x(77)90018-6

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  1 in total

1.  Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.

Authors:  Robert A Feldman; Yi-Lin Chiu; Cheri E Klein; Juki Ng
Journal:  Clin Pharmacokinet       Date:  2021-03-22       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.